{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Ffaq-ici-biomarkers-j428UrFu","width":444,"version":"1.0","type":"rich","title":"Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/fb2fd465-d3dc-4362-b1e1-21e77ceffc88/cliniciansxchange-onc-podcast-faq-ici-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/21618e6d-cb9a-4b09-b6aa-24b047865dfe\" height=\"200\" width=\"100%\" title=\"Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast episode, listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on the topic of current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced NSCLC."}